Early Breast Cancer Therapy and Cardiovascular Injury
Lee W. Jones, PhD*,*,
Mark J. Haykowsky, PhD ,
Jonas J. Swartz, BS*,
Pamela S. Douglas, MD and
John R. Mackey, MD
* Department of Surgery, Duke University Medical Center, Durham, North Carolina
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina
Faculty of Rehabilitation Medicine, Division of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
Faculty of Medicine, Division of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.
View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 The "Multiple-Hit" Hypothesis
A schematic representation describing the "multiple-hit" hypothesis. At diagnosis, a significant proportion of early breast cancer patients present with pre-existing or heightened cardiovascular disease (CVD) risk factors, which increase the risk of adjuvant therapy-associated cardiovascular injury. Independently, many adjuvant therapies used in breast cancer are associated with unique and varying degrees of direct adverse effects on the cardiovascular system. These direct effects occur in the context of concomitant lifestyle perturbations (indirect effects) that combine to reduce cardiovascular reserve. Collectively, these changes may leave the patient more susceptible to further cardiovascular insults and at higher risk of premature death due to cardiovascular mortality.
|
|
|
